FDA probes tumor risk in children treated with Novartis gene therapy Zolgensma

The FDA is investigating a potential link between Novartis' gene therapy Zolgensma and tumor formation in children, after the company disclosed two cases with evidence of a causal association. Nine tumor reports have been received overall. This raises safety concerns for a marketed gene therapy and could impact regulatory oversight and patient access.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works